dimethylmyleran

RN given refers to cpd without isomeric designation

Also Known As:

NSC 23890; dimethylbusulfan; dimethylmyleran, (+-)-isomer; dimethylmyleran, (meso)-isomer; 2,5-hexanediol dimethanesulfonate

Networked: 10 relevant articles (1 outcomes, 1 trials/studies)

1.	Ewing Sarcoma (Sarcoma, Ewing) 06/15/1981 - "A Ewing sarcoma grown in immunosuppressed mice was eradicated with a single lethal dose of dimethylmyleran (DMM) followed by autologous or syngeneic bone marrow. "
2.	Neoplasms (Cancer) 08/01/1981 - "Treatment of murine tumors with lethal doses of dimethylmyleran and autologous bone marrow." 11/01/1975 - "Effect of dimethylmyleran on cell-mediated immunity to a tumor allograft." 01/01/1987 - "Phase I study of high-dose dimethylbusulfan followed by autologous bone marrow transplantation in patients with advanced malignancy."
3.	Leukemia 03/01/1976 - "Use of dimethylmyleran in adoptive chemoimmunotherapy of two murine leukemias." 03/01/1976 - " Dimethylmyleran has been used in the treatment of garanulocytic leukemia, with a potency 3 times that of myleran (Busulphan). "
4.	Thalassemia 12/01/1985 - "Patients with thalassemia are treated with dimethylbusulfan 5 mg/kg or busulfan 14 mg/kg followed by CY 50 mg/kg on each of four days. "
5.	Leukopenia 10/01/1989 - "Four groups were studied: a control group, a second group receiving superoxide dismutase and catalase (SOD + CAT) on declamping, a third group receiving dimethylmyleran (DMM) 7 days before the experiment to obtain a selective leukopenia (white blood cells = 1,210 +/- 144/mm3, neutrophils = 1.2%), and a fourth group pretreated with allopurinol (ALLO). "

1.	Bone Marrow Transplantation (Transplantation, Bone Marrow)